To no surprise, Gilead Sciences’ Harvoni and Sovaldi were the top-selling infectious disease products in 2015.
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.
The bar for market success has been set high for baricitinib.
The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.
With drugs treating rare diseases priced at sky-high levels, can the healthcare system shoulder the financial burden they impose?
Please login or register first to view this content.